Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug ...

OpenAI advances recursive AI; new startup pursues self-improving systems amid leaked experimental model names.

Eric Schmidt and other AI leaders (Karpathy, Musk, Anthropic executives) have described recursive self-improvement (RSI)—AI autonomously designing, testing, and deploying better versions of itself—as ...

Abstract: This letter presents a novel method for environmental exploration that takes safety into account in unknown areas by using recursive Gaussian process regression (RGPR). Safety in unknown ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...